Synthon (PRIVATE.SYNTHON)

Overall impact
B (72)

Commentary

Synthon is a strong overall performer. With a 'B' rating of 73.5 for overall impact (87th percentile compared to all companies), Synthon ranks 58th out of 240 industry peers, behind Assembly Biosciences, Haleon, MedAvail and 54 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 179 others. On top material causes for Synthon's industry (Pharmaceuticals), Synthon performs well in Access to Affordable Healthcare (95.4 score), Access to Affordable Healthcare (95.4), Racial Justice and Civil Rights (83.8) and 18 other causes where it received an 'A' score and performs poorly in Equal Pay and Opportunity (37.2 score), Reduced Use of tobacco (39.4), Fair Labor Practices (37.7) and 9 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.SYNTHON
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1991
Employees
1,600
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Netherlands
Share classes
PRIVATE.SYNTHON
Description
Operator of a pharmaceutical company based in Nijmegen, Netherlands. The company specializes in developing and manufacturing generic and hybrid medicines, thereby making treatments more affordable and increasing access to important remedies.
Material causes
Ethos considers the following causes material for Synthon, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.